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A B S T R A C T
Opportunistic bacteria that cause life-threatening infections are still a central problem associated with a
healthcare setting. Bacteriophage capsid immobilization on nanostructured polymers maximizes its tail expo-
sure and looks promising in applications toward skin-infections as alternative to antibiotics standardly used.
The main goal of this work was to investigate the covalent immobilization of vB_Pae_Kakheti25 bacterio-
phage capsid on polycaprolactone (PCL) nanofibers (non-woven textile), as a potential effective antimicro-
bial, laundry resistant and non-toxic dressing for biomedical use. Surface analyses showed that the immobi-
lization of vB_Pae_Kakheti25 bacteriophage capsid on PCL nanofibres oriented bacteriophage tails to inter-
act with bacteria. Furthermore, antimicrobial assays showed a very effective 6 log bacterial reduction, which
was equivalent to 99.9999%, after immediate and 2 hours of contact, even following 25 washing cycles (due
to covalent bond). The activity of PCL-vB_Pae_Kakheti25 against P. aeruginosa was immediate and its re-
duction was complete.
© 2017.
The skin of patients with inflammatory skin-diseases alongside
with chronic or burn wounds and exit-sites of catheters is partic-
ularly susceptible to infection by different microorganisms. Oppor-
tunistic pathogens are the cause of skin diseases, infections, and the
inability of chronic wounds to heal.1–4 They are capable of produc-
ing virulence factors, including enzymes that promote tissue invasion
and extracellular polymers, which form the biofilm that contributes
to the perpetuation of skin inflammation, even in normal-appearing
skin. Fortunately, the majority of our resident skin microorganisms are
non-pathogenic and many of these contribute to maintaining health.1
Accordingly, skin-disease/injury management demands an integrated
approach aimed not only at diminishing infection but also at regulat-
ing the skin microbiome.2,5
P. aeruginosa is the most common infectious agent among
Pseudomonas spp. As a versatile and opportunistic microorganism it
can colonize the skin, soft tissue, gastrointestinal tract, armpits, eye
and ear.6–8 P. aeruginosa is the agent responsible for the most com-
mon infections under hospital settings, through catheter and ventila-
tor contaminations leading to nosocomial infections, such as pneumo-
nia, urinary tract and wound burn infections, as well as bacteremia,
especially in patients with diabetes or immunodeficiency.8 The major
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concerns about the control of nosocomial infections vary from the
problems of drug safety associated with a high human toxicity, the
long-term and large scale application of broad-spectrum antibiotic
drugs, to the increased resistance to conventional therapies. These in-
fections tend to chronicity and may fail to be treated with almost any
combination of antibiotics, showing mortalities up to 61%.9 The com-
bination therapy to fight P. aeruginosa infections is very difficult to
achieve, due to the compromised immune system of the majority of in-
fected patients, and the intrinsic resistance of microorganisms to vari-
ous antibiotics.10
Recent research has been conducted on the three groups of natu-
rally occurring antimicrobials as novel alternatives to antibiotics: bac-
teriophages, bacterial cell wall hydrolases (BCWHs), and antimicro-
bial peptides (AMPs).11 Among them, bacteriophages are the most
highly specific toward both Gram-positive and Gram-negative bac-
teria and they are also highly efficient and relatively cost-effective.
In contrast, AMPs have a broad-spectrum against bacteria and fun-
gus, low level of induced resistance, but may cause toxicity at high
doses in order to be efficient, and are more costly to produce.11 BCWH
has limitations toward Gram-negative bacteria, as a result of the pres-
ence of the outer membrane, and important Gram-positive pathogens
like S. aureus are already resistant to lysozymes. To overcome the
changing tide of nosocomial diseases and increasing reports of mi-
croorganism-acquired resistances, recently the United States, Canada
and European countries have started to take a close interest in bac-
teriophage-based therapies,12,13 in which they act without mecha-
nism-based host toxicity.
The bacteriophage vB_Pae_Kakheti25 has a potent activity against
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ventional treatments, especially as an antimicrobial agent for dressing.
It is representative of siphoviral family, has dsDNA as its genome,
icosahedral capsid, and long non-contractile tail. vB_Pae_Kakheti25
undergoes a lytic cycle through which it self-replicates and lyses a
broad range of P. aeruginosa strains in order to spread copies of itself.
Polycaprolactone (PCL), an hydrophobic polyester, can be ex-
plored as a substrate for skin regeneration due to its high elasticity and
slow biodegradability.14,15 Furthermore, it is not broken down by en-
zymes and microorganisms.14 These features seem worthy of dressing
applications.16
The textile and medical industries continue to look for eco-friendly
processes that may replace the currently used toxic textile chemicals
and the use of antibiotics, respectively.17–19 The demand for medici-
nal products alternative to antibiotics has increased considerably and
our proposed application seems promising due to its versatility, low
content of impurities, antistatic properties and good mechanical prop-
erties. Furthermore, as PCL is unfavorable for the development of mi-
croorganisms, its shelf life and users' health status are also ensured.
In this work, in order to eliminate the growth of P. aeruginosa,
PCL electrospun nanofibers were threaded and then vB_-
Pae_Kakheti25 bacteriophages were covalently immobilized by their
capsid via acid-amine reactions, forming amide linkages. The effect of
anti-P. aeruginosa activity of PCL-vB_Pae_Kakheti25 dressing was
evaluated under various parameters, so as to produce appropriate ap-
plications toward skin-infections, and aiming to further highlight the
potential of phage as the “antibiotic” of the millennium by minimizing
bacterial resistance and preserving skin-microbiome.
Methods
Materials
Polycaprolactone nanostructure (PCL), average Mn 45,000
(Sigma), was functionalized in a vB_Pae-Kakheti25 bacteriophage so-
lution. PA25 (DSM 25642) clinical isolates of Pseudomonas aerug-
inosa from the Eliava culture collection were used for isolation and
subsequent growth of vB_Pae-Kakheti25 bacteriophages. P. aerugi-
nosa was grown on Brain Heart Infusion (BHI) agar and then on Brain
Heart Infusion (BHI) broth (Sigma) at 30 °C and in shaker at 200 rpm.
Methods
Electrospinning
Nanofibers were produced by NanoSpider (Elmarco s.r.o. Liberec,
Czech Republic). PCL 15% (w/v) was dissolved in a mixture of ab-
solute ethanol/chloroform (65:35 vol.%) to prepare a homogeneous
solution. Different ratios of ethanol/chloroform solvents were used
in order to optimize the final nanostructure. The final concentration
of PCL and ratio of solvents were set according to the homogene-
ity of resulting nanofibers, their easy-detachment from polypropy-
lene-coated collecting electrode and tensile strength. The electrospin-
ning process was done under the following experimental conditions:
RH ≈65%, temperature ≈25 °C, electric voltage ≈80 kV, distance be-
tween electrodes = 8.98 cm, and electrode spin = 7 r/min (44 Hz).
Figure 1 shows the representative images of these nanofibers.
Tensile strength assays
Tensile strength of electrospun PCL was evaluated with resis-
tance-to-rupture assays. These assays were performed in a Dy
Figure 1. Polycaprolactone (PCL) 15% (w/V) electrospun fibers. Tendency of forming
layers of curlicues. 3000× magnification.
namometer (Thwing-Albert Instrument Co.) according to Standard EN
ISO 2062, at 20 ± 2 °C, under 60% relative humidity. Samples were
strip-cut 1×5 cm, with an average thickness of 50.33 μm, grammage
of 18.6 g/m2, and placed between dynamometer tweezers. A defined
pre-tension was set in the beginning, and the test ended with the rup-
ture of samples. Seven replicates were used.
Protein structure modeling – I-TASSER method
The sequence of amino acids (UniProtKB) of the Major capsid pro-
tein referred to as H6WTZ9–1 and Major tail tube protein referred to
























For the simulation, these sequences were threaded from Protein
Data Bank library, where multiple template alignments were gener-
ated. Then, the continuous fragments were excised, reassembed, clus-
tered and this full process was repeated. I-TASSER used the most sig-
nificant templates with the lowest energy.20–23 The predicted struc-
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Ninhydrin
In order to ascertain the presence of free amines on vB_-
Pae-Kakheti25 capsid, i.e. the estimation of the quantity of vB_-
Pae-Kakheti25 that PCL nanofibers were able to crosslink, ninhydrin
assays were done. Ninhydrin hydrates with amino groups, producing
purpurous Ruhemann's cromophore (λmax 570 nm). This colorimet-
ric assay was performed after drawing a calibration with known con-
centrations of L-cysteine. Each sample was added 2 mL of 108 vB_-
Pae-Kakheti25/ml and 1 ml of 8% Ninhydrin (acetone). ddH2O was
used for controls. Test tubes were placed in water bath at 100 °C for 10
minutes and then cooled down to room temperature before they were
read at 570 nm.
PCL substrate preparation
Nanofiber functionalization
After being formed with electrospinning, non-woven nanofibrous
PCL was washed for 4 hours with distilled water, at 40 °C, 110 rpm,
and dried afterwards at 30 °C until used, in order to remove any
surface residues and impurities. Samples were stored in the desic-
cator until use. For the activation of the surface, samples were sub-
mersed in acidic solution (pH 5.5) for 60 minutes at 40 °C. Soon af-
terwards they were washed in deionized water. After the activation
process, these were submitted to the functionalization process by ex-
haustion with vB_Pae-Kakheti25 bacteriophages via their amine com-
pounds. For the exhaustion functionalization process, a MOI of 0.1
vB_Pae-Kakheti25 bacteriophages was prepared. Each sample was
immersed in a bioactive solution at a liquor ratio of 1:50 in the beakers
of the Ahiba datacolor dyeing machine and submitted to 40 °C for 60
minutes. Finally, samples were washed in deionized water and stored
in the fridge.
Washing cycles assay – resistance to laundry
Laundry operations were performed before any characterization,
so as to assess PCL-vB_Pae-Kakheti25 covalent bonding resistance.
The methodology was adapted from the international standard EN ISO
105-C06:2010, as follows: (i) washing in ddH2O throughout 5 and 25
washing cycles, at 40 °C for 30 minutes each, and (ii) washing in a
4 g/L solution of AATCC 1993 Standard Reference Detergent WOB
throughout 5 and 25 washing cycles at 40 °C during 30 minutes each.
Fourier transform infrared spectroscopy (FT-IR)
The chemical arrangement of PCL nanostructure and PCL-vB_-
Pae-Kakheti25 was analyzed after three rinses (no washing cycles), 5
and 25 washing cycles with Thermo-Nicolet is10 spectrophotometer.
Samples were scanned 64 times, with a spatial frequency resolution of
4 cm−1.
Antimicrobial activity assessment
PCL-vB_Pae-Kakheti25 substrates were tested according to Japan-
ese Industrial Standard JIS L 1902:2002, designed to test all fabric
samples tailored to healthcare industry. Pseudomonas aeruginosa was
the selected agent once it is responsible for the most common in-
fections under hospital settings, with mortalities up to 61%.9 Briefly,
the inoculum of P. aeruginosa was adjusted to 1–5 × 106 bacteria/
mL, of which 200 μl were inoculated on 0.4 g PCL-vB_Pae-Kakheti25
circle samples. Following an incubation of 2 hours, antimicrobial
activity was calculated in order to determine bacterial
growth inhibition (% of Inhibition) at 2 hours:
Where C is the average value of Colony Forming Units (CFU) of
controls, and A represents the average value of CFU of PCL-vB_-
Pae-Kakheti25.
Growth kinetics of infected bacteria
One-step growth experiments were performed in order to evaluate
the latent phase and burst size of vB_Pae-Kakheti25, according to.24
Transmission electron microscopy (TEM)
The vB_Pae-Kakheti25 life cycle together with its host P. aerug-
inosa was monitored by TEM (HITACHI HT7700) at 0, 15, 30,
60 and 120 minutes. Furthermore, the bonding frequency of vB_-
Pae-Kakheti25 on PCL nanofibers was also visualized. Samples were
stained with 2% uranyl acetate during 5 minutes, and framed on a thin
bar copper web covered with formvar. Various magnitudes were used
at an accelerating voltage of 80 KV.
Cytotoxicity Activity Assay
The cytotoxicity of PCL-vB_Pae-Kakheti25 was performed ac-
cording to,25 in two different assays: perspiration extract assay and di-
rect contact assay. In the first assay, 2 g of PCL-vB_Pae-Kakheti25
samples were immersed for 24 h at 37 °C in PBS. The resulting per-
spiration extract was filtered (0.2um) and was then blended with cells,
at concentrations of 4.4, 6.6, 9.9, 14.8, 22.2, and 33.3%. The second
assay, direct contact assay, consisted in placing at the center of each
well a PCL-vB_Pae-Kakheti25 sample disc that covered 1/10 of its
area. Fibroblasts 3 T3 were used to seed each well at a concentration
of 2 × 104 cells/well. In the final part of both assays incubation was
conducted at 37 °C for 24 h, under a humidified atmosphere contain-
ing 5% O2. MTS viability assay was performed. Solvent, positive
and negative controls were included.
Statistical analysis
Statistics software SPSS 21.0 was used to calculate
one-way ANOVA and Tukey post-hoc tests for establishing multiple





Nanofibers were produced with an average thickness of 1.57
nm ± 0.26 Figure 1.
Tensile strength assays
Tensile tests evaluated the mechanical properties of developed
electrospun samples. Elastic modulus was observed for electrospun
PCL nanofibers (10.64 Mpa ± 2.99) with an elongation of
13.95% ± 2.43. Results between samples were not significantly differ-
ent, which means it demonstrated reproducibility.
Protein structure modeling
The predicted secondary structure of Major capsid protein was
arranged in globular domains, forming hexamers, comprised of alpha
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cording to the I-TASSER algorithm.16–19 Furthermore, the bioinfor-
matics modeling of these structures were generated using the
SPICKER program based on pair-wise structure similarity. C-scores
varied from −1.72 to −1.38. In Figure 2, A and B, it is presented
the structure predictions of Major capsid protein and Major tube pro-
tein, respectively. Non-polar side chains remained uncharged at phys-
iological pH and were incapable of participating in hydrogen bond-
ing. On the other hand, in Major tube protein, seven polar
leucine-15,47,88,112,178,385, and 464 were identified. Furthermore
four polar asparagine191,259,277, and 336 were detected, as well as
two polar glutamine-11 and 303. All of them contained an α-amino
group protonated at –NH3
+ under biological conditions. These are im-
portant for cross-linking to outer sheath proteins around Major tube
protein. Furthermore leucine-507, methionine-509, proline-510 and
aspartate-511 constitute an acidic terminal region, important to bind
and be capped by the spike protein.
The first subunit of the Major capsid protein presents polar ly-
sine-38 and glycine-45. Furthermore it presents an RGD se-
quence-44,45,46; aspartate-82,98, valine-85, and glycine-90,112 in
the second subunit; aspartate-144,148, leucine-132, valine-135, ser-
ine-137 in the third subunit; aspartate-157,174, serine-177,186, me-
thionine-184,189, histidine-185 in the fourth subunit; aspartate-224,
serine-225, valine-236, glycine-245, glutamate-259, asparagine-263 in
the fifth subunit; glycine-284 in the sixth subunit. Under physiological
conditions (pH 7.4) lysine, arginine, histidine side chains were posi-
tively charged –NH3
+ and important for covalent bonding to PCL sur-
face.
Ninhydrin
The free amines on vB_Pae-Kakheti25 capsid were quantified with
ninhydrin reagent. A calibration curve (r2 = 0.99) was performed with
known concentrations of L-cysteine (which contains only one amino
group), and finally, the concentration of amines in bacteriophage so-
lution was determined. Each bacteriophage was found to have 2.85
picogram of free amines.
Fourier transform infrared spectroscopy (FT-IR)
The FT-IR spectrum of unmodified nanofilm is shown in Figure
3, A. This spectrum displays the expected representative peaks of
polycaprolactone, namely C-H, related with CH2 stretching vibrations
at 2943 cm−1 and 2865 cm−1, and with carbonyl adsorption at 1721
cm−1.26
The covalent bonds between PCL and vB_Pae-Kakheti25 on
nanofibers, were also assessed by FT-IR after 5 and 25 washing cy-
cles. IR spectra showed PCL surface with carboxylic acid after its acti-
vation at 1712 cm−1, and vB_Pae-Kakheti25 grafted on nanofibers, as
denoted by the increase of the peaks owed to covalent bonds formed
with PCL surface, namely at 1667 cm−1 and 1541 cm−1, assigned to
Amide I and II, respectively, as well as the decrease of free carboxylic
acid at 1711 cm−1, as shown in Figure 3, B and C.
Antimicrobial assays
Quantitative method (suspension)
In order to evaluate the antimicrobial effectiveness of PCL-vB_-
Pae-Kakheti25, the adsorption test was performed to quantify the abil-
ity of nanofibers functionalized with bacteriophages to prevent bac-
terial growth Figure 4. The results showed that there were marked
reductions in Pseudomonas aeruginosa at T0 h and T2 h. PCL acti-
vated nanofibers showed outstanding microbial inhibition, as shown in
Figure 4. We could observe that PCL-vB_Pae-Kakheti25 eliminated 6
log of Pseudomonas aeruginosa at 0 and 2 hours, which was equiva-
lent to 99.9999% reduction.
After 5 and 25 washing cycles with WOB at 40 °C, the same 6 log
elimination of Pseudomonas aeruginosa was observed, either at 0 or
at 2-hour. These results proved that covalent bonding between PCL
and the bacteriophage capsid was stable and strong enough to resist to
several washings.
In order to know whether the samples behaved as bacteriosta-
tic or bactericidal, according to Japanese Industrial Standard JIS L
1902:2002, the bacteriostatic activity result can be not less than 2.0
and bactericidal activity result cannot be less than 0. Briefly, bacterio











Nanomedicine: Nanotechnology, Biology, and Medicine xxx (2017) xxx-xxx 5
Figure 3. IR spectra of unmodified PCL (A) and PCL-vB_Pae_Kakheti25 after (B) 5
washing-cycles and (C) 25 washing-cycles.
static activity = log10 of the average of bacterial colonies on the con-
trol samples at T24 h - log10 of the average of bacterial colonies on
the functionalized samples at T24 h; and bactericidal activity = log10
of the average number of bacterial colonies on the control samples at
T0 - log10 of the average of bacterial colonies on the functionalized
samples at T24 h.
The calculated values from these equations yielded the following
values: after three rinses, bacteriostatic activity was 0.94 and bacte-
ricidal activity was 1.63; after 5 washing cycles, bacteriostatic activ-
ity was 0 and bactericidal activity was 0.98; after 25 washing cycles,
bacteriostatic activity was 0 and bactericidal activity was 0. These re-
sults state that PCL-vB_Pae-Kakheti25 has a bactericidal effect after 3
rinses, 5 and 25 washing cycles, which means that the immobilization
of vB_Pae-Kakheti25 on PCL lead to death of P. aeruginosa and do
not interfere in the development and growth of bacteria.
Growth kinetics of infected bacteria
This assay aimed to study the growth kinetics of the infected host
cells, using a control (uninfected bacteria), at the dressing change tem-
perature of 29.9 °C Figure 5.
At this temperature the infected P. aeruginosa showed lower ab-
sorbance values than those obtained by the non-infected P. aerugi
nosa from 20 minutes after the beginning of incubation. This indicated
that vB_Pae-Kakheti25 had been using the bacterial machinery for its
benefit (latent period). A decrease in bacterial growth rate after 120
minutes were also observed, which indicated the onset of cell lysis
phase, resulting from bacteriophage infection.
Transmission electron microscopy (TEM)
The interaction between vB_Pae-Kakheti25 tail and P. aeruginosa
membrane is shown in Figure 6, A and B. The vB_Pae-Kakheti25 life
cycle inside P. aeruginosa cells was also monitored at 0, 20, 30, and
120 minutes, as shown in Figure 6, C-F. vB_Pae-Kakheti25 bacte-
riophage fiercely degraded P. aeruginosa membranes, especially after
20 minutes (Figure 6, D-F). Furthermore, the spacing of the bonding
of vB_Pae-Kakheti25 on PCL after 25 washing cycles was also vi-
sualized, as shown in Figure 7. The frequency of covalent bonds of
vB_Pae-Kakheti25 on PCL nanofibers averaged 118 nm, as shown in
Figure 7, A.
Tumoral activity assay
PCL-vB_Pae-Kakheti25 did not show any cytotoxic effect over
mouse fibroblast cell line BALB/c 3 T3 Figure 8. Both perspiration
extract assay and direct contact assay showed values that did not
ranged beyond 30% from controls. Only an alteration under or over
30% in comparison with controls would be considered cytotoxic or
pro-tumorigenic, respectively.21
Discussion
As part of natural defenses of ecosystem, the mode of action of
bacteriophages is very specific and relies on infecting exclusively
their host bacteria, leaving the rest of microbiota and human tis-
sues intact. In this investigation, the capsid of the bacteriophage vB_-
Pae-Kakheti25 was covalently cross-linked to polycaprolactone (PCL)
nanofibrous dressing, in order to maximize vB_Pae-Kakheti25 tail
exposure, evaluate its stability, and its antimicrobial effect over
Pseudomonas aeruginosa bacteria. The electrospun nanofibrous struc-
tures offer larger area of contact and a smoother surface, which dimin-
ishes roughness and scratching.27
A nanofibrous dressing with an average thickness of 1.57 nm was
produced by electrospinning. For the covalent immobilization of bac-
teriophage capsid onto PCL nanofibers, the first step was the forma-
tion of reactive acid groups on PCL, namely ester groups (−COO-)
that were hydrolyzed to carboxylic acid groups from ester under acidic
solution (pH 5.5) via the reverse of Fischer esterification.
Figure 4. Percentage of microbial inhibition at 0 hours (A) and 24 hours (B) – all of these values were obtained by comparison with results of native PCL. *Statistically significant
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Figure 5. One-step growth kinetics of P. aeruginosa strain and P. aeruginosa infected with the bacteriophage vB_Pae-Kakheti25 at 29.9 °C.
Figure 6. Adsorption of vB_Pae-Kakheti25 to P. aeruginosa membrane at 50000× magnification, (A) and (B). vB_Pae-Kakheti25 life cycle infecting P. aeruginosa monitored at 0
(C), 20 (D), 30 (E), and 120 minutes (F). 6000× and 25,000× magnifications.
Amino groups of vB_Pae-Kakheti25 capsid – 2.85 picogram of free
amines per bacteriophage – reacted as soon as they contacted the car-
boxylic acids of PCL, via acid-amine reactions, forming amide link-
ages. vB_Pae-Kakheti25 bacteriophage contains an icosahedral head
structure that is composed of many copies of Major capsid protein
(UniProtKB) with 325 amino acid length and lysine, arginine, histi-
dine side chains that were positively charged under physiologic pH.
Also vB_Pae-Kakheti25 presents a tail that recognizes surface recep
tors of P. aeruginosa. Mechanical properties of PCL nanofibers
showed high elasticity and were not significantly altered in any treat-
ments in this study, which means PCL structure was not degraded dur-
ing the experiment.
Fourier Transform Infrared Spectroscopy (FT-IR) and Transmis-
sion Electron Microscopy (TEM) provided evidence for the proposed
bacteriophage immobilization aligned in a head-to-tail orientation.
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Figure 7. The bonding frequency of vB_Pae-Kakheti25 to PCL single nanofibre (A), 3D visualization (B), and vB_Pae-Kakheti25 adsorption arrangement (C). 10,000×, 30,000×
and 40,000× magnifications.
Figure 8. Perspiration extract assay and direct contact assay against mouse fibroblast cell line BALB/c 3 T3.
immobilized on PCL surface, by the comparison of peak height pro-
portions (1667 cm−1, 1541 cm−1 and 1711 cm−1) between PCL and
PCL grafted with vB_Pae-Kakheti25. Furthermore, spectra showed
the covalent cross-link between PCL and vB_Pae-Kakheti25 to be
multiple washing-resistant – 5 and 25 washing cycles – and conse-
quently stable, because the aforementioned peaks height proportions
were maintained. In accordance with these previous data, TEM im-
ages showed vB_Pae-Kakheti25 immobilized on PCL nanofibers and
aligned in a head-to-tail orientation after it had been washed 25 times.
Immobilized bacteriophages were also spaced ≈118 nm apart on both
sides.
Antimicrobial assays of vB_Pae-Kakheti25-bearing PCL showed
that it acted as soon as it contacted with P. aeruginosa, with an-
timicrobial reducing rates of 99.9999% (6 log), p < 0.05. In addi-
tion, PCL-vB_Pae-Kakheti25 was identically active after 25 washing
cycles, either at immediate contact, or at 2-hour contact. These re-
sults were higher than the 5 log reduction observed by Huang et al.
for silver-chitosan.28 The low natural adhesion of PCL29 due to its
hydrophobic character - contact angle of 109.9° ± 5.0°29 – may also
have facilitated the contact of P. aeruginosa with the bacteriophage
tails. H. Yang and Y. Deng30 also showed that a hydrophobic surface
reduced adhesion capacity of PCL to bacteria.30
Although Karumidze et al24 studied the effect of vB_-
Pae-Kakheti25 on P. aeruginosa, the immobilization of vB_-
Pae-Kakheti25 on whichever surface has not been reported yet. Since
a vB_Pae-Kakheti25 multiplicity of infection of 0.1 led to a general
growth inhibition of P. aeruginosa in BHI agar plates,24 it would be
assured that a surface functionalized with the same amount of vB_-
Pae-Kakheti25 would also kill P. aeruginosa, especially due to its
maximized tail exposure and the larger area of contact of electrospun
nanofibers. On the other hand, when in solution, vB_Pae_Kakheti25
bacteriophages aggregated together by generating bonds between their
tails, and consequently decreasing their accessibility to interact with
P. aeruginosa, as also proposed by Langlet et al.31
The growth kinetics was studied at 29.9 °C, which is the temper-
ature of the dressing change procedure. The P. aeruginosa was ob-
served to halt its exponential growth as it became infected by vB_-
Pae-Kakheti25 bacteriophage. This demonstrated that as soon as P.
aeruginosa was infected, vB_Pae-Kakheti25 used its machinery for
self-replication, the so-called latent period. The lysis phase began
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120 minutes, where P. aeruginosa mainly undergone the release of re-
cently-formed bacteriophages.
Our samples were adequately tested on mouse fibroblast cell line
in order to ascertain whether they were cytotoxic. The perspiration ex-
tract of samples showed an average cell growth inhibition of 5.3% and
the direct contact assay showed an average growth enhancement of
0.33%. A variation of growth of more than 30% in comparison with
the controls is regarded as cell-toxic effect.32 Therefore, the cytotox-
icity assay for PCL-vB_Pae-Kakheti25 showed less than 30% of cel-
lular viability reduction, making our invention a safe agent for use in
contact with skin.
While there are a few commercial antimicrobial applications, they
present limitations. Dermasilk® is a silk-based material with Si-QAC
(Silane quaternary ammonium compounds) combining the smooth-
ness of silk with the antimicrobial properties.2,33 Another example is
Padycare® a micromesh polyamide/lycra containing woven silver fil-
aments.34 Similarly, TheraBond® is a silver fabric dressing designed
to optimize wound fluid management without compromising the an-
timicrobial properties.2,3 In vitro studies of these garments demon-
strated a significant decrease in P. aeruginosa. Even though there is
no evidence for skin sensitization by bulk silver, a possible systemic
absorption of silver particles because of a disrupt skin barrier has
to be considered, while Si-QAC is reported to cause bacterial resis-
tance and show evidence of skin sensitization.2,33,35 For this reason,
the relatively lower incidence of adverse reactions of natural products
has been intensively investigated.4,33,35 Overall, antimicrobial textiles
have found uses in hygienic rather than medical field especially due to
possible cytotoxic effect and sometimes low effectiveness.4,35 Antimi-
crobial textiles have been designed to address activity against a broad
spectrum of microorganisms33,35,36 but there remain open questions re-
garding toxicity on human health, which is causing a paradigm change
to move on to highly specific agents toward pathogenic bacteria. Like-
wise, the rising flow of strains resistant to last-resort antibiotics rekin-
dles interest in novel approaches.11,35–37
Phage immobilization strategies on organic and inorganic surfaces
have been recently reported37–45: while in some cases electrostatic
binding showed phage instability and detachment,46 covalent attach-
ment offers a much stronger bond.47 Still, for antimicrobial surfaces
designed to utilize the inherent binding specificity and lytic activity of
phage toward the bacterial host, tailed phage should be immobilized
through the capsid and filamentous phage with their bacterial-captur-
ing pole exposed.44–46
Therefore, in this work we surface-anchored vB_Pae-Kakheti25
bacteriophages to develop highly specific antibacterial non-woven
textiles/dressings especially – but not limited to – for skin associated
infections, as a skin microbiome regulator. Such textiles could also
find application as outside catheter dressings to provide adequate fix-
ation and inhibition of bacterial adhesion during catheter lifetime. To
authors' knowledge this is the first investigation exploiting phages as
antibacterial agents for textiles. The closest approach that one can con-
sider related has been reported by Mao et al.,48 where a non-lytic fil-
amentous phage (M13) was engineered to express negatively-charged
glutamates further glutaraldehyde-crosslinked upon extrusion of fibers
and Kevlar coatings with the ability to attract Ag+ in a silverization
process. The engineered phage was the basis of the fiber and coating
but silver was responsible for the antibacterial activity since non-lytic
phage was used. Our strategy, in contrary, immobilized lytic phage
onto non-woven textile as antibacterial agent.
This study showed that vB_Pae-Kakheti25 covalent immobiliza-
tion on PCL nanofibers with a head-to-tail orientation added antimi-
crobial properties to the proposed dressing. It presented a microbial
reduction of 6 log, even after 25 wash cycles, comparatively with the
non-modified nanostructure after 2 h of incubation. Its activity was
immediate and P. aeruginosa reduction was complete.
On the contrary, when in solution, vB_Pae_Kakheti25 bacterio-
phage aggregated and decreased its availability to interact with P.
aeruginosa.
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